In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 30 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.